Journals / Düşünen Adam - Psikiyatri ve Nörolojik Bilimler Dergisi / 2018 / Cilt: 31 - Sayı: 4

A Case of Stuttering Due to Olanzapine Treatment

Olanzapin kullanımına bağlı gelişen bir kekemelik olgusu

Pages
405–408
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Theimportance of this case is to show that while olanzapine may be used in the treatment of stuttering,it may also be the cause of stuttering as an adverse effect.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Stuttering is defined as a disturbance in time patterning and fluency of speech inappropriate for anindividual’s age.
📊
Key Findings & Data:Some studies show thatstuttering is related with an increased number of D2 receptors in the basal ganglia.
💡
Conclusion & Impact:Theimportance of this case is to show that while olanzapine may be used in the treatment of stuttering,it may also be the cause of stuttering as an adverse effect.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Stuttering is defined as a disturbance in time patterning and fluency of speech inappropriate for anindividual’s age. The pathophysiology of stuttering is not fully understood. Some studies show thatstuttering is related with an increased number of D2 receptors in the basal ganglia. Otherwise, a50-200% increase in the level of dopaminergic activity has been found in stuttering cases in comparisonto the control group. Stuttering as a side-effect of psychotropic medication is rare. Only a fewstuttering cases are reported in the literature as being due to effects of antipsychotics likechlorpromazine, clozapine, olanzapine, risperidone, or trifluoperazine. Olanzapine is also used to treatthe symptoms of stuttering via D2 receptor antagonism, and in the literature there are cases treatedwith the administration of olanzapine. Here we present a case of olanzapine-induced stuttering. Theimportance of this case is to show that while olanzapine may be used in the treatment of stuttering,it may also be the cause of stuttering as an adverse effect.

Özet

Kekemelik; yaşla uyumsuz olarak konuşmanın akıcılığı ve zamanlamasındaki bozukluk olarak tanımlanır. Etiyolojisi halen tam olarak bilinmemektedir. Yayınlanmış bazı çalışmalar kekemeliğin bazal gangliyonlarda artmış D2 reseptör seviyesiyle ilişkili olduğunu göstermiştir. Ayrıca kekemelik olgularında kontrol grubuna göre %50-200 oranında artmış dopaminerjik aktivite saptanmıştır. Kekemelik nadiren psikotropik ilaçların yan etkisi olarak ortaya çıkmaktadır. Literatürde az sayıda klorpromazin, klozapin, olanzapin, risperidon ve trifluperazin kullanımına bağlı gelişmiş kekemelik olguları mevcuttur. Aynı zamanda olanzapinin D2 reseptör antagonizması yaparak kekemelik semptomlarını düzelttiğini belirten olgular da yayınlanmıştır. Bu olgu sunumunda olanzapin kullanımına bağlı gelişen bir kekemelik olgusu sunduk. Bu olgu olanzapinin kekemelik semptomlarının tedavisinde kullanılmasının yanı sıra, bir yan etki olarak kekemeliğe yol açabildiğini göstermesi açısından önemlidir.

🔖

Cite This Article

ASAN, Ö., YAYLACI, E. T., GOKA, E., TATLIDİL, E. (2022). A Case of Stuttering Due to Olanzapine Treatment. Düşünen Adam - Psikiyatri ve Nörolojik Bilimler Dergisi, Cilt: 31 - Sayı: 4, 405–408. https://ajindex.com/articles/493718

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Maguire GA, Yeh CY, Ito BS. Overview of the diagnosis and treatment of stuttering. J Exp Clin Med 2012; 4:92-97. [CrossRef] American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders Fourth Ed., Text Revision. Washington, DC; 2000. Guitar BE. Stuttering and stammering. Pediatr Rev 1985; 7:163- 168. [CrossRef] Maguire G. Without Hesitation: Speaking to the Silence and the Science of Stuttering. New York, NY: National Stuttering Association, 2010.
  2. Andrews G, Craig A, Feyer A, Hoddinott S, Howie P, Neilson M. Stuttering: a review of research findings and theories circa 1982. J Speech Hear Disord 1983; 48:226-246. [CrossRef] Aras S. Communication Disorders: In Gulec C, Koroglu E (editors). Foundations of Psychiatry. Second ed., Ankara: Physicians’ Publishing Union, 2007, 777-797. (Turkish) Ashurst JV, Wasson MN. Developmental and persistent developmental stuttering: an overview for primary care physicians. J Am Osteopath Assoc 2011; 111:576-580.
  3. Belgin E, Derinsu U. Incidence of speech and voice disorders in primary school children. 19. National Turkish Congress of Otorhinolaryngology. Istanbul, 1990, 158-160. (Turkish) Bloodstein O. A Handbook on Stuttering, Fifth Ed., San Diego: Singular Publishing Group, 1995. Blood GW. Laterality differences in child stutterers: heterogeneity, severity levels, and statistical treatments. J Speech Hear Disord 1985; 50:66-72. [CrossRef] Wu JC, Maguire G, Riley G, Lee A, Keator D, Tang C, Fallon J, Najafi A. Increased dopamine activity associated with stuttering. Neuroreport 1997; 8:767-770. [CrossRef] Wu JC, Maguire G, Riley G, Fallon J, LaCasse L, Chin S, Klein E, Tang C, Cadwell S, Lottenberg S. A positron emission tomography [18F] deoxyglucose study of developmental stuttering. Neuroreport 1995; 6:501-505. [CrossRef] Anderson JM, Hughes JD, Rothi LJ, Crucian GP, Heilman KM. Developmental stuttering and Parkinson’s disease: the effects of levodopa treatment. J Neurol Neurosurg Psychiatry 1999; 66:776-778. [CrossRef] Rosenberger PB, Wheelden JA, Kalotkin M. The effect of haloperidol on stuttering. Am J Psychiatry 1976; 133:331-334. [CrossRef] Rothenberger A, Johannsen HS, Schulze H, Amorosa H, Rommel D. Use of tiapride on stuttering in children and adolescents. Percept Mot Skills 1994; 79:1163-1170.
  4. Maguire G, Riley GD, Franklin DL, Gottschalk LA. Risperidone for the treatment of stuttering. J Clin Psychopharmacol 2000; 20:479-482. [CrossRef] Maguire GA, Riley G, Franklin DL, Maguire ME, Nguyen